Junshi Biosciences’ New Cancer Drug Trial Approved
Company Announcements

Junshi Biosciences’ New Cancer Drug Trial Approved

Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.

Shanghai Junshi Biosciences Co., Ltd. has announced the approval of their Investigational New Drug application for WJ47156 tablets, used in clinical trials for advanced malignant tumors treatment. The drug, JS125, is a selective inhibitor targeting histone deacetylases (HDACs), which play a role in tumor development and treatment. Investors are cautioned of the inherent high-risk nature of pharmaceutical development and encouraged to consider the investment risks carefully.

For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App